
|Videos|April 1, 2014
The Challenges of Measuring Tumor Heterogeneity
Author(s)Ari Melnick, MD
Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses the challenges associated with measuring tumor heterogeneity.
Advertisement
Clinical Pearls
Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses the challenges associated with measuring tumor heterogeneity.
- Measuring variability requires looking at many methylated sites in the genome, which is unlikely to become a routine test
- There remains a need for a way to measure tumor heterogeneity in a reliable and meaningful way
- Researchers are currently looking for si​tes in the genome that may be a surrogate marker for genome-wide profiling
- It is impossible to target diversity from the genetic standpoint, though epigenetic diversity could be targeted
- Hypothetically, drugs could demethylate the genome to make it more uniform
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5









































